ScholarWorks@Hanyang University: Yoo, Dae Hyun

Detailed Information

Yoo, Dae Hyun (유대현)

COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 류마티스내과

Tel 02-2290-9202
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Rheumatoid arthritis:21||rheumatoid arthritis:17||CTP13:11||biosimilar:11||s disease:10||infliximab:9||Ankylosing spondylitis:8||Safety:8||Arthritis:7||rheumatoid:7||treatment:6||Rheumatoid Arthritis:6||Infliximab:6||ankylosing spondylitis:5||arthritis:5||adultonset Still&apos:5||pharmacokinetics:5||polymorphism:4||TNF inhibitor:4||Tacrolimus:4||Biosimilar:4||Rheumatoid:4||Efficacy:4||Inflammatory myopathy:4||immunogenicity:4||Interstitial lung disease:4||tocilizumab:4||Prognosis:3||genetic:3||Treatment:3||CTP10:3||Epidemiology:3||Adult onset Still&apos:3||DMARDs (biologic):3||Mortality:3||antiTNF:3||safety:3||Disease activity:3||switching:3||Osteoporosis:3||Korean:3||Pharmacokinetics:3||Polymyositis:3||Myositis:2||Chronic kidney disease:2||Adalimumab:2||biologic:2||Risk factors:2||Rituximab:2||S DISEASE:2||Azotemia:2||Incidence:2||macrophage activation syndrome:2||lupus nephritis:2||Immunogenicity:2||rituximab:2||Uveitis:2||Malignancy:2||Proteinuria:2||Discordance:2||Latent Tuberculosis Infection:2||subcutaneous:2||RA:2||Interleukin18:2||Latent tuberculosis:2||DMARD:2||systemic lupus erythematosus:2||B cells:2||Acute myocardial infarction:2||interleukin:2||BuddChiari syndrome:2||DAS28:2||etanercept:2||tuberculosis:2||Behcet&apos:2||Apoptosis:2||connective tissue disease:2||Korea:2||Effectiveness:2||Tumor necrosis factor inhibitor:2||Prevalence:2||Treatment Outcome:2||dermatomyositis:2||Korean patients:2||disease activity:2||outcome measure:2||osteoporosis:2||Rhematoid arthritis:2||Remission:2||anakinra:2||polymyositis:2||mycophenolate mofetil:2||Inflammatory Myopathy:1||InterferonGamma Release Assay:1||Interferongamma release assay:1||Intravenous:1||Isoniazid:1||Janus Kinase Inhibitor:1||Janus kinase (JAK):1||Juvenile rheumatoid arthritis:1||Korean National Health Insurance reimbursement criteria:1||Late onset:1||Latent tuberculosis infection:1||Lung:1||Lupus erythematosus, Systemic:1||MACROPHAGE ACTIVATION SYNDROME:1||MEFV:1||MRI:1||MYCOBACTERIUM TUBERCULOSIS:1||Macrophages:1||Mapping:1||Melittin:1||Methotrexate:1||NATURAL KILLER CELL:1||NFkappa B:1||NFAT:1||NSAIDs:1||Natural killer T cell:1||Neoplasm:1||Network metaregression:1||Nontuberculous mycobacteria infection:1||OCCULT INFECTION:1||Opportunistic infection:1||Osteoarthritis:1||Osteoblast:1||Osteocalcin:1||PI3K/Akt:1||Pain:1||Patient global assessment:1||Peripheral arthritis:1||Physician global assessment:1||PlaceboControlled Clinical Trial:1||Pneumomediastinum:1||Polymorphism:1||Polymyalgia Rheumatica:1||Predictor:1||Psoriatic arthritis:1||Pulmonary:1||Pulmonary arterial hypertension:1||Pulmonary hypertension:1||Quality of life:1||QuantiFERONTB gold in tube test:1||RHEUMATIC DISEASES:1||RHEUMATOID ARTHRITIS:1||Rac1:1||Recommendation:1||Registries:1||Registry:1||Reimbursement guidelines:1||Rheumatic diseases:1||RhoA:1||Risk Factors:1||SEX:1||SINGLENUCLEOTIDE POLYMORPHISMS:1||SKIN TEST:1||STAT3:1||SW982 human synovial cells:1||Seropositive rheumatoid arthritis:1||Sharp score:1||Sleep:1||Spondylitis, Ankylosing:1||Subcutaneous:1||Synoviocyte:1||Systemic lupus erythematosus:1||Systemic onset:1||T2T:1||TNF antagonist:1||TNF inhibitors:1||TNFalpha:1||TNFalpha blockers:1||TNFblocker:1||TNFRFc Fusion Protein:1||TUBERCULIN:1||TUBERCULOSIS:1||TUMOR NECROSIS FACTOR:1||TUMOR NECROSIS FACTOR BLOCKER:1||TUMOR NECROSIS FACTORalpha BLOCKER:1||Tocilizumab:1||Treattotarget:1||Treatment response:1||Tuberculosis:1||Tumor necrosis factoralpha:1||Tumour necrosis factor inhibitor:1||USA:1||Uratelowering efficacy:1||Uric acid:1||Utility:1||Whole Body Bone Scan:1||acquired amegakaryocytic thrombocytopenia:1||adverse effects:1||affordability:1||alphagalactosylceramide:1||angiotensinconvening enzyme:1||antirheumatic agents:1||autoantibody:1||autoimmune diseases:1||autoimmune hemolytic anemia:1||baricitinib:1||biobetter:1||bioinformatics:1||biologic agent:1||biologic therapies:1||biologic therapy:1||biological agents:1||biological therapy:1||biomarkers:1||bone density:1||bone mineral density:1||bucillamine:1||canakinumab:1||cardiovascular diseases:1||clinical studies:1||clinical trials and methods:1||cohort study:1||combination therapy:1||comorbidity:1||complete remission:1||consensus recommendations:1||corticosteroids:1||cyclophosphamide:1||cyclosporine:1||cytokine:1||diagnosis:1||dose adjustment:1||drug survival:1||early arthritis:1||education:1||effectiveness:1||efficacy:1||equivalence:1||fasciitis:1||femur:1||fluvastatin:1||healthy subjects:1||immunosuppressants:1||inflammation:1||inflammatory bowel disease:1||infliximab biosimilar:1||infusion interval adjustment:1||interferon:1||interleukin18:1||interleukin33:1||interleukin37:1||interleukin6:1||latent tuberculosis infection:1||literature search:1||malignancy:1||methotrexate:1||microheterogeneity:1||monitoring:1||morning stiffness:1||myositis:1||nasaltype NK/T cell lymphoma:1||neoplasms:1||nocebo effect:1||noninferiority:1||outcome:1||pemphigus:1||peptidyldipeptidase A:1||prospective study:1||protein phosphatase magnesiumdependent 1 A:1||pulmonary arterial hypertension:1||pulmonary hypertension:1||radiographic progression:1||randomized controlled study:1||realworld data:1||refractory:1||registries:1||remission:1||rheumatic disease:1||s disease (AOSD):1||scleroderma:1||statistics:1||survival:1||switch:1||systemic:1||systemic sclerosis:1||tacrolimus:1||transcriptome:1||tuberculin skin test:1||tumor necrosis factor inhibitor:1||tumour necrosis factor antagonist:1||vertebral fracture:1||고요산혈증:1||관해:1||단백뇨:1||대사증후군:1||류마티스 관절염:1||류마티스관절염:1||만성콩팥병:1||생물학적 제제:1||식이요법:1||약물 치료:1||조기관절염:1||질소혈증:1||치료:1||통풍:1||1,25Dihydroxyvitamin D3:1||활성도:1||ACR20:1||ADULT ONSET STILL&apos:1||ADULTONSET STILL&apos:1||ANKYLOSING SPONDYLITIS:1||ASAS:1||Abatacept:1||Additional Blood Pool Phase:1||Adult onset Still’s disease:1||Adultonset still&apos:1||Adverse Event:1||Amino acid:1||Ankylosing Spondylitis:1||AntiCCP antibody:1||AntiTNF:1||AntiTNF alpha agents:1||AntiTNF drugs:1||AntiTumor Necrosis Factor:1||Antirheumatic:1||Antirheumatic agents:1||Arthritis, rheumatoid:1||Autoimmune diseases:1||Azathioprine:1||BAFF:1||Biologic DMARDs:1||Biologic DiseaseModifying Antirheumatic Drugs:1||Biological products:1||Biological therapy:1||Biosimilars:1||Bone Mineral Density:1||Bone density:1||Bone marrow:1||CD1d:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||CONVERSION:1||COX2 inhibitor:1||Calcineurin:1||Celecoxib:1||Clinical Effectiveness:1||Clinical characteristics:1||Clinical trial:1||Cohort:1||Cohort studies:1||Comorbidity:1||Copy number variations:1||Corticosteroids:1||Cyclosporine:1||Cytokine:1||DEPRESSION:1||DMARDs:1||Death:1||Dermatomyositis:1||Dermatomyositis/polymyositis:1||Diagnostic Performance:1||Drug efficacy:1||Drug persistency:1||Drug retention rate:1||E148Q:1||EQ5D:1||Early diagnosis:1||East Asia:1||Elderly:1||Etoricoxib:1||European Union:1||Extension Study:1||Fatigue:1||Fc gamma RECEPTOR:1||Febuxostat:1||Fracture:1||Fractures:1||Frequency:1||Gastrointestinal diseases:1||Gout:1||HAQ:1||HAQDI:1||HEPATITIS B VIRUS:1||HLADRB1:1||HOUSEHOLD:1||Health services research:1||Hemorrhage:1||Hypertension:1||Hypouricemia:1||IL1 beta:1||IL6:1||INTERLEUKIN 18:1||INTERLEUKIN 18 BINDING PROTEIN:1||Idiopathic inflammatory myopathy:1||Idiopathic inflammatory myositis:1||Indeterminate:1||Indirect treatment comparison:1||Individual patient data:1||Inflammation:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE